Biofrontera

Biofrontera reports a 17% revenue increase in Q1 2026 to $10.1 million and a gross margin of 80% versus 62% a year earlier, driven by higher Ameluz sales and price increases. Operating loss narrowed slightly; net loss was $4.8 million, or $0.41 per share. Management attributes the margin improvement to a strategic transaction and a new earn-out structure and expects 2026 revenue to reach $46.76 million with positive EPS in Q4 2026. » Altro su de.investing.com

Biofrontera reports record revenue of USD 17.1 million in Q4 2025 (+36% year-on-year) and its first net profit of USD 5.6 million. The cost structure improved markedly following a strategic transaction with Biofrontera AG, reducing COGS by 45% and lifting the gross margin to 82%; adjusted EBITDA was USD 4.9 million (29% margin). The pre-market share price rose 7.07% to USD 0.93. Management expects further revenue growth and full realization of the cost benefits in 2026, as well as upside potential from product developments and possible FDA approvals. » Altro su de.investing.com

Biofrontera has completed the pharmacokinetic phase‑1 study of Ameluz in actinic keratoses on the neck, trunk and extremities; 17 patients received treatment and blood samples were analyzed over 10 hours. The data will feed into the planned supplemental new drug application (sNDA) to the FDA, which the company expects in summer 2026, to expand the indication beyond the face and scalp. In parallel, the approval plan includes results from a recently completed phase‑3 study; financially, Biofrontera reported declining revenue and a higher net loss, while Benchmark maintained its buy recommendation with a target price of USD 3.00. » Altro su de.investing.com